Total submissions: 1
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV003064492 | SCV003443316 | likely pathogenic | Glycogen storage disease, type II | 2022-05-30 | criteria provided, single submitter | clinical testing | In summary, the currently available evidence indicates that the variant is pathogenic, but additional data are needed to prove that conclusively. Therefore, this variant has been classified as Likely Pathogenic. Studies have shown that disruption of this splice site results in skipping of exon 2, and is expected to result in the loss of the initiator methionine (PMID: 31301153). Disruption of this splice site has been observed in individual(s) with Pompe disease (PMID: 22252923). This variant is not present in population databases (gnomAD no frequency). This sequence change affects a donor splice site in intron 2 of the GAA gene. RNA analysis indicates that disruption of this splice site induces altered splicing and is likely to result in the loss of the initiator methionine. |